Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic

J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S807-S814. doi: 10.1093/ecco-jcc/jjaa125.

Abstract

The rapid emergence of the novel coronavirus [SARS-CoV2] and the coronavirus disease 2019 [COVID-19] has caused significant global morbidity and mortality. This is particularly concerning for vulnerable groups such as pregnant women with inflammatory bowel disease [IBD]. Care for pregnant IBD patients in itself is a complex issue because of the delicate balance between controlling maternal IBD as well as promoting the health of the unborn child. This often requires continued immunosuppressive maintenance medication or the introduction of new IBD medication during pregnancy. The current global COVID-19 pandemic creates an additional challenge in the management of pregnant IBD patients. In this paper we aimed to answer relevant questions that can be encountered in daily clinical practice when caring for pregnant women with IBD during the current COVID-19 pandemic.

Podcast: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast.

Keywords: Pregnancy; COVID-19; SARS-CoV2; inflammatory bowel disease.

MeSH terms

  • Betacoronavirus* / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Coronavirus Infections / complications
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / prevention & control*
  • Disease Progression
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / therapy*
  • Pandemics / prevention & control*
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / prevention & control*
  • Pregnancy
  • Pregnancy Complications / therapy*
  • Risk Assessment
  • SARS-CoV-2
  • Severity of Illness Index

Substances

  • Immunosuppressive Agents